Proximal Ventures has assembled a $27.5 million pool backed by prominent institutions like Kleiner Perkins, SignalFire, and Bertelsmann Healthcare Investments. The capital will target automated solutions designed to replace outsourced pharmaceutical services. The firm has already completed investments in six portfolio companies, including ChronicleBio, an enterprise co-founded by former OpenAI executive Fidji Simo. Backers expect the strategy to yield strong co-investment opportunities alongside major venture firms.
Key points
Artificial intelligence is targeted to automate molecular compound synthesis and clinical…: Artificial intelligence is targeted to automate molecular compound synthesis and clinical trial analysis to cut drug development expenses.
Former FDA principal deputy commissioner Amy Abernethy joined top venture firms like Klei…: Former FDA principal deputy commissioner Amy Abernethy joined top venture firms like Kleiner Perkins as a fund backer.
The investment approach is guided by Sahir Raoof's prior experience at Flatiron Health, w…: The investment approach is guided by Sahir Raoof's prior experience at Flatiron Health, which Roche acquired for $1.9 billion.
Sources checked by our analysis pipeline: 1
While established venture firms continue to attract capital, first-time fund managers are facing one of the toughest fundraising environments in years. But that didn’t stop Sahir Raoof, a former SignalFire investor and executive at two healthcare startups, from raising $27.5 million for his first solo VC fund.
Raoof’s firm, Proximal Ventures, is betting that AI can transform the tools, infrastructure, and services that support drug development.
Pharmaceutical companies have historically outsourced various stages of drug development to specialized service providers, from synthesizing thousands of molecular compounds and figuring out how to manufacture drugs at scale to analyzing clinical trial data.
“For a long time, the assumption was that pharma is not a great buyer of software, but a really good buyer of services,” Raoof told TechCrunch.
Raoof believes AI could automate much of that work, creating an opportunity for startups to capture billions of dollars in pharmaceutical industry spending. By using AI, these companies could deliver the same services at a lower cost and in significantly less time, he said.
Some of the most valuable applications of AI so far…
Regulatory documentation confirms a massive post-market capital injection aimed at strengthening ties between the leading chipmaker and the artificial intelligence startup. The scheduled funding represents a tenth of the total fresh capital Anthropic expects to secure across its concurrent fundraising and public listing this month. This maneuver underscores the intense strategic alignment and aggressive financing characterizing the current frontier technology sector.
Large-scale developers must now publish their safety frameworks and submit to state scrutiny to avoid severe financial penalties. The legislative push expands state-level oversight across the nation while establishing dedicated research bodies to evaluate cutting-edge models. This framework ensures that high-earning tech companies proactively disclose transparency reports and critical incidents rather than operating unchecked.
Artificial intelligence agents frequently struggle with context retention when navigating disparate file types across complex workflows. Graphon aims to eliminate these operational constraints by establishing meaningful structural relationships across diverse media formats. The newly acquired capital will directly support the development of this cross-modal data mapping technology.